Exclusive Q&A With : Dr. Sanjay Koul, Director of Mankind Pharma
Updated on: 30 Jun 2016
With a strong turnover of Rs. 4,000 crore in the 2015-16 fiscal, Mankind Pharma has managed to hold an strong market position so far. The brand aims to bring more products to the wellness category in the years to come. But, tight lipped over this year's expected turnover.
"For now, it's too early to make any definitive statement," said Dr. Sanjay Koul, Director, Mankind Pharma, in an exclusive interaction with WI Bureau. Here is what the brand plans about its wellness products.
What are the key factors enhancing the growth of your brand in the Indian wellness space?
We are determined to offer products of the highest quality and prices that are suitable for buyers with different spending capacities, along with a dedicated team to make sure both these goals are achieved, is what boosts the growth of our brand in the field of Indian wellness.
What are the major challenges of being a potential player in this segment? How did you overcome the challenges with other existing market challenges like competitors, availability of resources and revenue generation?